GlobeNewswire: Aravive, Inc. Contains the last 10 of 205 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T00:57:20ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/01/17/2811132/0/en/Aravive-Inc-to-Delist-from-The-Nasdaq-Stock-Market.html?f=22&fvtc=4&fvtv=21227Aravive, Inc. to Delist from The Nasdaq Stock Market2024-01-17T21:09:41Z<![CDATA[HOUSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), announced today that the Company intends to voluntarily terminate the listing of its common stock on the Nasdaq Global Select Market (“Nasdaq”) and, based upon ownership of its shares by fewer than 300 holders of record, deregister its common stock under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and suspend its public reporting obligations.]]>https://www.globenewswire.com/news-release/2023/08/02/2717335/0/en/Aravive-Announces-Top-Line-Results-from-Phase-3-AXLerate-OC-Study-of-Batiraxcept-in-Platinum-Resistant-Ovarian-Cancer.html?f=22&fvtc=4&fvtv=21227Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer2023-08-02T20:01:00Z<![CDATA[HOUSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that its Phase 3 AXLerate-OC trial evaluating the safety and efficacy of batiraxcept in platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in the pre-specified subset of patients naïve to prior bevacizumab treatment. The trial did not show any difference between the two arms in the overall population (which included patients previously treated with bevacizumab). The Company will continue to evaluate the complete dataset and determine next steps in the development of batiraxcept.]]>https://www.globenewswire.com/news-release/2023/07/28/2713027/0/en/Aravive-to-Present-Updated-Clinical-Data-from-Batiraxcept-Trials-in-Renal-and-Pancreatic-Cancer-at-ESMO-Congress-2023.html?f=22&fvtc=4&fvtv=21227Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 20232023-07-28T11:05:00Z<![CDATA[HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the acceptance of two abstracts for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2023, being held October 20-24, 2023 in Madrid, Spain. Posters will feature clinical data from the Company’s ongoing Phase 1b/2 trials of batiraxcept in clear cell renal cell carcinoma (ccRCC) and pancreatic adenocarcinoma (PDAC).]]>https://www.globenewswire.com/news-release/2023/07/14/2704921/0/en/Aravive-to-Participate-in-William-Blair-s-Innovator-Series-Transitioning-Biotech-Breakthroughs-to-Commercial-Success-Being-Held-July-18-2023.html?f=22&fvtc=4&fvtv=21227Aravive to Participate in William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 20232023-07-14T11:05:00Z<![CDATA[HOUSTON, July 14, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer will be participating in a fireside chat at the William Blair Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success being held virtually on July 18, 2023.]]>https://www.globenewswire.com/news-release/2023/06/13/2687645/0/en/Aravive-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c.html?f=22&fvtc=4&fvtv=21227Aravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)2023-06-13T20:05:00Z<![CDATA[HOUSTON, June 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that in accordance with Nasdaq rules regarding employment inducement awards, the Company has granted an equity compensation award to a new employee.]]>https://www.globenewswire.com/news-release/2023/06/05/2682366/0/en/Aravive-To-Participate-in-the-Jefferies-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=21227Aravive To Participate in the Jefferies Global Healthcare Conference2023-06-05T20:05:00Z<![CDATA[HOUSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial Officer will be presenting a corporate overview and participating in 1x1 meetings at the Jefferies Global Healthcare Conference being held on June 7-9, 2023 in New York, NY.]]>https://www.globenewswire.com/news-release/2023/05/25/2676762/0/en/Aravive-to-Present-Promising-Updated-Data-from-Phase-2-Trial-of-Batiraxcept-in-Combination-with-Cabozantinib-in-Clear-Cell-Renal-Cell-Carcinoma-at-ASCO-2023.html?f=22&fvtc=4&fvtv=21227Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 20232023-05-25T21:00:00Z<![CDATA[HOUSTON, May 25, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of updated results from its ongoing Phase 2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) annual meeting, taking place June 2-6, 2023 in Chicago, IL and virtually. The poster presentation will highlight updated results from the Phase 2 portion of the trial in patients with advanced or metastatic ccRCC with or without prior line(s) of therapy, including immuno-oncology (IO)- and vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI)-based therapies. In addition, an abstract highlighting batiraxcept data in pancreatic adenocarcinoma (PDAC) will be published in the 2023 ASCO Annual Meeting Proceedings.]]>https://www.globenewswire.com/news-release/2023/05/16/2669831/0/en/Aravive-Announces-Phase-3-Trial-Design-for-Batiraxcept-in-Clear-Cell-Renal-Cell-Carcinoma.html?f=22&fvtc=4&fvtv=21227Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma2023-05-16T11:05:00Z<![CDATA[HOUSTON, May 16, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that the Company has received guidance from the U.S. Food and Drug Administration (FDA) on a registrational Phase 3 trial design for batiraxcept in clear cell renal cell carcinoma (ccRCC) at an End-of-Phase 2 (EOP2) meeting.]]>https://www.globenewswire.com/news-release/2023/05/10/2666057/0/en/Aravive-Reports-First-Quarter-2023-Financial-Results-and-Provides-Corporate-Updates.html?f=22&fvtc=4&fvtv=21227Aravive Reports First Quarter 2023 Financial Results and Provides Corporate Updates2023-05-10T20:05:00Z<![CDATA[HOUSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported first quarter 2023 financial results and provided corporate updates.]]>https://www.globenewswire.com/news-release/2023/05/08/2663168/0/en/Aravive-to-Host-Virtual-KOL-Event-on-its-Late-Stage-Oncology-Asset-Batiraxcept.html?f=22&fvtc=4&fvtv=21227Aravive to Host Virtual KOL Event on its Late-Stage Oncology Asset Batiraxcept2023-05-08T11:05:00Z<![CDATA[Webinar to take place on Wednesday, May 24, 2023 at 1:00pm ET Webinar to take place on Wednesday, May 24, 2023 at 1:00pm ET]]>